You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.

Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound

found 2025 › Jul › 16 (Wed) @ 18:10 UTC

Healthy ■■
Chinese ■■
Eli Lilly ■■
Hengrui Pharma ■■
Kailera Therapeutics ■■
China ■■■
Anne Wojcicki ■■

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's nonprofit acquires 23andMe.